{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/lipid-modification-cvd-prevention/management/lipid-therapy-primary-prevention-of-cvd/","result":{"pageContext":{"chapter":{"id":"ec817edb-2375-548c-beb5-8afb1596d294","slug":"lipid-therapy-primary-prevention-of-cvd","fullItemName":"Scenario: Lipid therapy - primary prevention of CVD","depth":2,"htmlHeader":"<!-- begin field e5a05268-3a1f-4d3d-9159-66dd48685c40 --><h2>Scenario: Lipid therapy - primary prevention of CVD</h2><!-- end field e5a05268-3a1f-4d3d-9159-66dd48685c40 -->","summary":"Covers the primary prevention of cardiovascular disease (CVD) with lipid modification therapy.","htmlStringContent":"<!-- begin item d1c74671-4d04-4331-b5af-08a74bf63e16 --><!-- begin field 656eb43a-f42b-4cc7-b7c7-acbc0155a10b --><p>From age 18 years onwards.</p><!-- end field 656eb43a-f42b-4cc7-b7c7-acbc0155a10b --><!-- end item d1c74671-4d04-4331-b5af-08a74bf63e16 -->","topic":{"id":"5303951d-71d9-506d-84ec-cbdd7ff3b93e","topicId":"dc4f1ad8-1fac-4248-9071-a622ca58dd2c","topicName":"Lipid modification - CVD prevention","slug":"lipid-modification-cvd-prevention","lastRevised":"Last revised in October 2020","chapters":[{"id":"7834a360-a716-55db-beef-e74397381f6b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"4149ed5c-ad54-5793-8860-4b2f82d94427","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"184e9f02-cec5-5813-a428-f3b70683deda","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0fd087eb-ba58-59e6-b641-2161dd021687","slug":"changes","fullItemName":"Changes"},{"id":"6e535866-055b-5f94-8d43-67cc6c3262a6","slug":"update","fullItemName":"Update"}]},{"id":"6952071a-0b87-50ea-af6b-c7589b86f9bd","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"3de1ddbe-7a0f-5384-9939-9a56d2251dfc","slug":"goals","fullItemName":"Goals"},{"id":"1a8df6be-f747-5d74-81cf-54d938d5944b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"80c40530-2e39-55a1-910d-b5226d83d67a","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e9906a94-72bf-5a9e-8e05-bb7b6841fec3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"507f0f33-704f-5b79-813e-0ba2a367617e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c55b24f4-39a4-5919-8e05-5afc7b1ae5c6","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f02326a5-5f6d-5026-9c8c-745fd760df23","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f4e4cb23-7f1d-5543-a7a5-9316a25c589b","slug":"lipids-cardiovascular-health","fullItemName":"Lipids and cardiovascular health"}]},{"id":"5123c607-afa6-5c07-a939-547efe27b94c","fullItemName":"Management","slug":"management","subChapters":[{"id":"ec817edb-2375-548c-beb5-8afb1596d294","slug":"lipid-therapy-primary-prevention-of-cvd","fullItemName":"Scenario: Lipid therapy - primary prevention of CVD"},{"id":"4cd90098-cba6-5b78-994c-9fc173b4fb3f","slug":"lipid-therapy-secondary-prevention-of-cvd","fullItemName":"Scenario: Lipid therapy - secondary prevention of CVD"}]},{"id":"35a2dc51-a5b3-56bd-9a02-c420e08c1d0d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"3e6af82a-f8f1-5d90-a988-05136fa101f3","slug":"statins","fullItemName":"Statins"}]},{"id":"238b503e-9352-5458-b356-3f6b521ef218","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2dbe7113-fbe3-5fd2-bca1-2846dd9a39c8","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"fbe34d96-9294-5a30-8de1-1bc1f631ce69","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"df527078-d479-5b6f-aff8-247af2cdd323","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1a8284ce-a2e5-59db-9d07-596f590c3ec3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"9fe03c85-09a6-5232-8343-e77d91ad6145","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d5bce13d-7bb2-5366-8bcc-28f538824ee4","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f5e3b9df-860b-5c62-a358-a408038abc28","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"5123c607-afa6-5c07-a939-547efe27b94c","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"ed08f0a2-0543-5fac-aed6-554f8eafdd4a","slug":"when-to-offer-therapy","fullItemName":"When to offer therapy","depth":3,"htmlHeader":"<!-- begin field da0d8857-e8b0-42a2-b35f-86c497920a74 --><h3>When should I offer lipid modification therapy for primary prevention of cardiovascular disease?</h3><!-- end field da0d8857-e8b0-42a2-b35f-86c497920a74 -->","summary":null,"htmlStringContent":"<!-- begin item 29006b69-d8b4-4f5d-ba32-fc0797426b9f --><!-- begin field c87d1673-097e-4185-ac48-617155e9810a --><ul><li><strong>Offer lipid modification therapy</strong> <strong>to people aged 84 years and younger if their estimated 10-year risk of developing cardiovascular disease (CVD) using the <a href=\"https://qrisk.org/three/\" data-hyperlink-id=\"799e88b4-a4fc-4997-ab98-aa95009109d7\">QRISK</a> assessment tool is 10% or more and lifestyle modification is ineffective or inappropriate. </strong><ul><li>Also, offer lipid modification therapy to people with type 2 diabetes who have a 10% or greater 10-year risk of developing CVD. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a>.</li></ul></li><li><strong>Consider offering lipid modification therapy (without the need for a formal risk assessment)</strong> <strong>to all people with type 1 diabetes.</strong> </li><li><strong>Offer lipid modification therapy</strong><strong> (without the need for a formal risk assessment) to people with:</strong> <ul><li>Type 1 diabetes who:<ul><li>Are aged more than 40 years.</li><li>Have had diabetes for more than 10 years or have established nephropathy. </li><li>Have other CVD risk factors.</li></ul></li><li>Chronic kidney disease — for more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/chronic-kidney-disease/\">Chronic kidney disease</a>. </li><li>Familial hypercholesterolaemia — for more information, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/hypercholesterolaemia-familial/management/adults-with-heterozygous-fh/#lipid-modification-treatment-in-adults-with-heterozygous-fh\">Lipid-modification treatment in adults with heterozygous FH</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypercholesterolaemia-familial/\">Hypercholesterolaemia - familial</a>. </li></ul></li><li><strong>Consider offering lipid modification therapy</strong> (without the need for a formal risk assessment) to people who aged 85 years or over (particularly people who smoke or have raised blood pressure), taking into account the risks and benefits of treatment, additional factors such as potential benefits from lifestyle modifications, informed patient preference, comorbidities, polypharmacy, general frailty and life expectancy.</li><li>For more information on assessing 10-year CVD risk, and when it is appropriate to use the <a href=\"https://qrisk.org/three/\" data-hyperlink-id=\"036a54b3-3a84-4efc-9d97-aa950092f90d\">QRISK</a> assessment tool, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a>. </li></ul><!-- end field c87d1673-097e-4185-ac48-617155e9810a --><!-- end item 29006b69-d8b4-4f5d-ba32-fc0797426b9f -->","subChapters":[{"id":"a95d5c3c-dbf3-5228-bac5-95ff763e2f10","slug":"basis-for-recommendation-7a0","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 8e9a824d-440e-4b7c-9fb6-b63e2f0119e9 --><h4>Basis for recommendation</h4><!-- end field 8e9a824d-440e-4b7c-9fb6-b63e2f0119e9 -->","summary":null,"htmlStringContent":"<!-- begin item 7a02bbf1-55f1-4305-a4dc-f44a3352da6f --><!-- begin field d1acf9a3-4dfa-4d9a-9085-f4c296bf1e95 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">NICE, 2016a</a>], and <em>Familial hypercholesterolaemia: identification and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">NICE, 2017b</a>].  </p><h5>When to offer lipid modification therapy following the QRISK assessment</h5><ul><li>NICE has determined that the treatment threshold for primary prevention of CVD is a CVD risk of 10% as assessed using QRISK [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">NICE, 2016a</a>]. </li><li>However, in the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Risk estimation and the prevention of cardiovascular disease,</em> this threshold remains at 20% [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">SIGN, 2017</a>].   <ul><li>SIGN states that while the NICE approach identifies the proportion of the population which is cost effective to treat, it is less clear how the additional workload was accounted for within primary care to implement the policy, and the societal ramifications of the threshold effectively (placing almost all people in England and Wales above 65 years of age at high risk of CVD) were not explored.</li><li>In Scotland, almost 95% of individuals are at 10% or greater risk of a cardiovascular event within 10 years by the age of 60–64. Implementing this threshold in Scotland would increase the total number of people eligible for preventive treatment by around 70% to over 1.3 million.</li></ul></li></ul><h5>When to consider lipid modification therapy without the need for a formal risk assessment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">NICE, 2016a</a>]</h5><ul><li>The NICE guideline development group (GDG) considered that all people aged 85 years and older are at high risk of CVD by virtue of age alone and therefore have a greater likelihood of clinical benefit with lipid modification treatment.</li><li>In addition, the QRISK tool has an upper limit of 84 years and is therefore not applicable to people aged 85 years and over.</li></ul><!-- end field d1acf9a3-4dfa-4d9a-9085-f4c296bf1e95 --><!-- end item 7a02bbf1-55f1-4305-a4dc-f44a3352da6f -->","subChapters":[]}]},{"id":"3ca1d358-5781-5fab-96e4-3e8918e1aecc","slug":"interventions-tests-before-drug-treatment","fullItemName":"Interventions and tests before drug treatment","depth":3,"htmlHeader":"<!-- begin field 18a25fc7-7672-46fb-8e4b-57b1e257476c --><h3>What interventions and tests should I implement before starting lipid modification treatment for the primary prevention of cardiovascular disease?</h3><!-- end field 18a25fc7-7672-46fb-8e4b-57b1e257476c -->","summary":null,"htmlStringContent":"<!-- begin item c5abb6b1-0ed3-43f3-94c8-1f8d7f0bcc21 --><!-- begin field 6f1bae58-2891-4304-93f9-6d89d7343ef1 --><ul><li><strong>Before offering lipid modification treatment for primary prevention: </strong><ul><li>Use the clinical findings, lipid profile and family history to judge the likelihood of a familial lipid disorder — for more information on diagnosing or excluding familial hypercholesterolaemia as a cause of dyslipidaemia, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypercholesterolaemia-familial/\">Hypercholesterolaemia - familial</a>. </li><li>Exclude possible secondary causes of dyslipidaemia (such as excess alcohol, uncontrolled diabetes, hypothyroidism, liver disease and nephrotic syndrome). </li><li>Discuss the benefit of lifestyle modifications and optimize the management of all other modifiable CVD risk factors, including any relevant comorbidities that may not be optimally treated.<ul><li>Offer the opportunity to reassess CVD risk again after they have tried to change their lifestyle. </li><li>Recognise that some people may need support to change their lifestyle — to help, refer them to programmes such as exercise referral schemes or smoking cessation services.</li></ul></li><li>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a> for more information.</li></ul></li><li><strong>Perform the following baseline blood tests (if not already done as part of the cardiovascular risk assessment):</strong><ul><li><strong>Lipid measurement </strong>—<strong> </strong>at least one lipid sample should be taken to measure a full lipid profile. This should include measurement of total cholesterol, high-density lipoprotein cholesterol (HDL-C) cholesterol, non-HDL-C (the difference between total and HDL-C), and triglycerides. A fasting sample is <em>not </em>needed. For people with:<ul><li><strong>A total cholesterol of more than 7.5 mmol/L and a family history of premature coronary heart disease</strong> — consider the possibility of familial hypercholesterolaemia. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypercholesterolaemia-familial/\">Hypercholesterolaemia - familial</a>. </li><li><strong>A total cholesterol of more than 9.0 mmol/L</strong>, <strong>or non-HDL cholesterol concentration of more than 7.5 mmol/L</strong> (even in the absence of a first-degree family history of premature coronary heart disease) — arrange for specialist assessment. </li><li><strong>A triglyceride concentration of more than 20 mmol/L</strong> that is not a result of excess alcohol or poor glycaemic control — refer for urgent specialist review. </li><li><strong>A triglyceride concentration between 10–20 mmol/L</strong> — repeat the triglyceride measurement with a fasting test (after an interval of 5 days, but within 2 weeks), review for potential secondary causes of hyperlipidaemia, and seek specialist advice if the triglyceride concentration remains above 10 mmol/L. </li><li><strong>A triglyceride concentration between 4.5–9.9 mmol/L</strong> — be aware that the CVD risk may be underestimated by risk assessment tools and optimize the management of other CVD risk factors present. Seek specialist advice if non-HDL cholesterol concentration is more than 7.5 mmol/L in this group of people. </li></ul></li><li><strong>Creatine kinase (CK) </strong>— ask the person if they have persistent generalized unexplained muscle pain (whether associated with previous lipid-lowering therapy or not). <ul><li>If present, measure CK level:<ul><li>If the CK level is raised but is less than five times the upper limit of normal, start statin treatment at a lower dose. </li><li>If the CK level is five or more times the upper limit of normal, re-measure after 7 days. If levels are still five times the upper limit of normal, do not start statin treatment (seek specialist advice). </li></ul></li></ul></li><li><strong>Liver function tests (alanine aminotransferase or aspartate aminotransferase) </strong>— if these results are abnormal, perform further investigations to determine the cause of the abnormal test results (for example non-alcoholic fatty liver disease). <ul><li>Do not routinely exclude from treatment people who have liver enzymes that are elevated but are less than three times the upper limit of normal. </li></ul></li><li><strong>Renal function (including estimated glomerular filtration rate) </strong>— chronic kidney disease (CKD) does not preclude the use of a lipid-lowering drug, as these people are at increased risk of CVD. However, specific doses are recommended depending on the stage of CKD. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/chronic-kidney-disease/\">Chronic kidney disease</a>. </li><li><strong>HbA1c<sub> </sub></strong>— to diagnose diabetes mellitus. For more information, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/diagnosis/diagnosis-in-adults/\">Diagnosis</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a>. <ul><li>Lipid-lowering treatment should not be stopped due to acute elevations in blood glucose. </li><li>See the sections on lipid modification in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-1/\">Diabetes - type 1</a> and <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a> for information on prescribing a lipid-lowering drug to a person with diabetes mellitus.</li></ul></li><li><strong>Thyroid stimulating hormone </strong>— to detect a thyroid disorder.</li></ul></li><li><strong>Also ensure the following are included in a clinical assessment before starting statin treatment: </strong><ul><li>Alcohol consumption.</li><li>Blood pressure.</li><li>Body mass index.</li><li>Smoking status.</li></ul></li></ul><!-- end field 6f1bae58-2891-4304-93f9-6d89d7343ef1 --><!-- end item c5abb6b1-0ed3-43f3-94c8-1f8d7f0bcc21 -->","subChapters":[{"id":"36d08e82-7bb1-5717-96ed-223b351c4914","slug":"basis-for-recommendation-c92","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 6db37a19-8e77-4b28-97f8-bd44018714e8 --><h4>Basis for recommendation</h4><!-- end field 6db37a19-8e77-4b28-97f8-bd44018714e8 -->","summary":null,"htmlStringContent":"<!-- begin item c927db0c-a7ff-4529-b793-8d7d5e8c3ad8 --><!-- begin field 70989bc7-64f1-4ee1-bf50-e5078558a8d0 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">NICE, 2016a</a>], the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Risk estimation and the prevention of cardiovascular disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">SIGN, 2017</a>], the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">Joint Formulary Committee, 2019</a>], the manufacturer's Summary of Product Characteristics for atrovastatin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">ABPI, 2018</a>], and what CKS considers good clinical practice.</p><!-- end field 70989bc7-64f1-4ee1-bf50-e5078558a8d0 --><!-- end item c927db0c-a7ff-4529-b793-8d7d5e8c3ad8 -->","subChapters":[]}]},{"id":"74163e5a-31c2-5456-8089-7cae3906757e","slug":"first-line-therapy","fullItemName":"First-line therapy","depth":3,"htmlHeader":"<!-- begin field 6c1785c0-664f-4469-8639-68b621b32380 --><h3>Which first-line lipid modification therapy should I offer for primary prevention of CVD?</h3><!-- end field 6c1785c0-664f-4469-8639-68b621b32380 -->","summary":null,"htmlStringContent":"<!-- begin item 00f76c80-3795-4de2-a2b1-ecb83d92a63e --><!-- begin field 8525e6c0-c961-41f6-9627-dffb508c9233 --><ul><li><strong>Offer high intensity statin treatment unless this is <a class=\"topic-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/prescribing-information/statins/#cautions-contraindications\">contraindicated</a> (for example in pregnancy). </strong></li><li><strong>Discuss the risks and benefits of statin treatment so that the person can make an informed choice about their treatment. </strong>Advise that: <ul><li>High intensity statin treatment is the most clinically effective option for the prevention of cardiovascular disease (CVD). However, statins at any <a class=\"topic-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/management/lipid-therapy-primary-prevention-of-cvd/#grouping-of-statins\">intensity</a> reduce CVD risk compared with no treatment.</li><li>The <a class=\"topic-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/prescribing-information/statins/#adverse-effects\">adverse effects</a> of statins are generally mild, reversible, and not medically serious, although some people may find them distressing. <ul><li><a class=\"topic-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/prescribing-information/statins/#adverse-effects\">Myopathy and rhabdomyolysis</a> are the most serious adverse effects of statins. However, they are rare, with estimated incidences of 5 cases per 100,000 person years and 1.6 cases per 100,000 person years, respectively. </li></ul></li></ul></li><li><strong>If the person is willing to take a statin:</strong><ul><li>Prescribe atorvastatin 20 mg once a day. </li><li>Advise that:<ul><li>Statin treatment should be adhered to, and should be combined with lifestyle measures (such as increase physical activity, reduce alcohol consumption, adopt a diet that helps reduce CVD risk). For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a>. </li><li>Other drugs, some foods (for example, grapefruit juice) and some supplements may interfere with statins and to always consult the information leaflet, a pharmacist or prescriber for advice when starting other drugs or thinking about taking supplements. </li><li>The statin should be restarted if they stopped taking it because of drug interactions or when treating intercurrent illnesses.</li><li>They should seek medical advice if they develop <a class=\"topic-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/prescribing-information/statins/#adverse-effects\">adverse effects</a> such as unexplained muscle symptoms (pain, tenderness, or weakness). </li></ul></li><li><a class=\"topic-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/management/lipid-therapy-primary-prevention-of-cvd/#follow-up\">Follow up</a> the person to assess the effectiveness and tolerability of treatment. </li></ul></li><li><strong>If statins are contraindicated, </strong>consider seeking specialist advice.<ul><li>Do not routinely prescribe fibrates. </li><li>Do not offer bile acid sequestrants, nicotinic acid, omega-3 fatty acid compounds, or any of these (or a fibrate) in combination with a statin. </li><li>Do not offer coenzyme Q10 or vitamin D to increase adherence to statin treatment.</li><li>Consider treatment with ezetimibe for people with primary hypercholesterolaemia.</li></ul></li><li>See <a class=\"topic-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/prescribing-information/statins/\">Prescribing information</a> for detailed information on the use of statins.</li><li><strong>If the person declines treatment with a statin, </strong>advise that their CVD risk should be reassessed again at a later date. Record their choice in their medical notes.</li></ul><!-- end field 8525e6c0-c961-41f6-9627-dffb508c9233 --><!-- end item 00f76c80-3795-4de2-a2b1-ecb83d92a63e -->","subChapters":[{"id":"d01c123e-3f0f-5480-94e7-0581b8006b4e","slug":"grouping-of-statins","fullItemName":"Grouping of statins","depth":4,"htmlHeader":"<!-- begin field 9348a873-9b73-45d6-9e5c-59ddf318ad2c --><h4>Grouping of statins</h4><!-- end field 9348a873-9b73-45d6-9e5c-59ddf318ad2c -->","summary":null,"htmlStringContent":"<!-- begin item 5789b87e-f311-4291-ba2c-aa25e520ff84 --><!-- begin field 3cbdcdec-7cc5-40bc-b088-a9cc37a58a3e --><ul><li>Statins are grouped into low intensity, medium intensity, and high intensity, according to the percentage reduction in low density lipoprotein cholesterol (LDL-C) they can produce. See Table 1 for details of the NICE grouping of statins available in the UK.</li></ul><p><strong>Table 1</strong><strong>. </strong>Grouping of statins available in the UK according to intensity of LDL-C reduction (%).</p><table><thead><tr><th colspan=\"1\"><p>High intensity</p><p>(above 40%) </p></th><th colspan=\"1\"><p>Medium intensity </p><p>(31–40%)</p></th><th colspan=\"1\"><p>Low intensity</p><p>(20–30%)</p></th></tr></thead><tbody><tr><td colspan=\"3\"><strong>Atorvastatin</strong></td></tr><tr><td colspan=\"1\">20 mg (43%)</td><td colspan=\"1\">10 mg (37%)</td><td colspan=\"1\"> </td></tr><tr><td colspan=\"1\">40 mg (49%)</td><td colspan=\"1\"> </td><td colspan=\"1\"> </td></tr><tr><td colspan=\"1\">80 mg (55%)</td><td colspan=\"1\"> </td><td colspan=\"1\"> </td></tr><tr><td colspan=\"3\"><strong>Simvastatin</strong></td></tr><tr><td colspan=\"1\">80 mg (42%)</td><td colspan=\"1\">20 mg (32%)</td><td colspan=\"1\">10 mg (27%)</td></tr><tr><td colspan=\"1\"> </td><td colspan=\"1\">40 mg (37%)</td><td colspan=\"1\"> </td></tr><tr><td colspan=\"3\"><strong>Pravastatin</strong></td></tr><tr><td colspan=\"1\"> </td><td colspan=\"1\"> </td><td colspan=\"1\">10 mg (20%)</td></tr><tr><td colspan=\"1\"> </td><td colspan=\"1\"> </td><td colspan=\"1\">20 mg (24%)</td></tr><tr><td colspan=\"1\"> </td><td colspan=\"1\"> </td><td colspan=\"1\">40 mg (29%)</td></tr><tr><td colspan=\"3\"><strong>Fluvastatin</strong></td></tr><tr><td colspan=\"1\"> </td><td colspan=\"1\">80 mg (33%)</td><td colspan=\"1\">20 mg (21%)</td></tr><tr><td colspan=\"1\"> </td><td colspan=\"1\"> </td><td colspan=\"1\">40 mg (27%)</td></tr><tr><td colspan=\"3\"><strong>Rosuvastatin</strong></td></tr><tr><td colspan=\"1\">10 mg (43%)</td><td colspan=\"1\">5 mg (38%)</td><td colspan=\"1\"> </td></tr><tr><td colspan=\"1\">20 mg (48%)</td><td colspan=\"1\"> </td><td colspan=\"1\"> </td></tr><tr><td colspan=\"1\">40 mg (53%)</td><td colspan=\"1\"> </td><td colspan=\"1\"> </td></tr><tr><td colspan=\"3\"><strong>Adapted from:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">NICE, 2016a</a>]</td></tr></tbody></table><!-- end field 3cbdcdec-7cc5-40bc-b088-a9cc37a58a3e --><!-- end item 5789b87e-f311-4291-ba2c-aa25e520ff84 -->","subChapters":[]},{"id":"1712fae9-c8ba-58e8-8cfb-748750977683","slug":"basis-for-recommendation-488","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field b867a7df-cfc6-4b6f-b29b-3d7e30e55af9 --><h4>Basis for recommendation</h4><!-- end field b867a7df-cfc6-4b6f-b29b-3d7e30e55af9 -->","summary":null,"htmlStringContent":"<!-- begin item 488e28c5-e309-4e40-9c95-3d74d4eb8341 --><!-- begin field af5f6519-ea63-49f1-993a-0fbc156331e4 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">NICE, 2016a</a>], the NICE technology appraisal <em>Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">NICE, 2016b</a>], the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Risk estimation and the prevention of cardiovascular disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">SIGN, 2017</a>], the Medicines and Healthcare products Regulatory Agency (MHRA) drug safety update <em>Statins: benefits and risks</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">MHRA, 2014</a>], and what CKS considers good clinical practice.  </p><h5>Choice of high-intensity statin</h5><ul><li>NICE did not identify any head-to-head trials on the effectiveness of the high-intensity statins (in terms of reducing clinical end points) for the primary prevention of CVD. The GDG therefore assumed equivalent effectiveness between all high-intensity statins, but atorvastatin was preferred to simvastatin 80 mg and all strengths of rosuvastatin because:<ul><li>Simvastatin 80 mg is associated with an increased risk of myopathy. The NICE GDG concluded that since equivalent or greater benefits can be obtained from atorvastatin, with a lower risk of myopathy, there is no reason for considering initiating simvastatin 80 mg for the primary prevention of CVD [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">NICE, 2016a</a>]. In addition, a meta-analysis found simvastatin 80 mg to have a lesser effect in reducing low-density lipoprotein cholesterol (LDL-C) compared with atorvastatin 20 mg, 40 mg, and 80 mg [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">Law et al, 2003</a>].</li></ul></li><li>However, a NICE surveillance report states that at the time the guideline was developed the committee was unable to judge if rosuvastatin 10 mg, 20 mg or 40 mg would be more effective than atorvastatin 80 mg in reducing CVD events, and as it was considerably more expensive (as a generic form was not available), that in the absence of trial evidence of greater effectiveness the guideline committee was unable to recommend the use of rosuvastatin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">NICE, 2018</a>], but that new evidence was now available that may change these recommendations: <ul><li>An individual patient data meta-analysis of 37 studies (n = 32,258) which assessed the extent to which high-intensity statins (rosuvastatin 20-40 mg and atorvastatin 40-80 mg) reduced LDL-C in each of four statin benefit groups, found reductions in LDL-C with rosuvastatin 20 and 40 mg were greater than with atorvastatin 40 mg overall and in each statin benefit group, and with rosuvastatin 40 mg were greater than with atorvastatin 80 mg overall and in three of the four benefit groups [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">Karlson, 2015</a>]. </li><li>A large randomized controlled trial (n = 12,705) which evaluated the long-term effects of rosuvastatin at a dose of 10 mg per day (without dose adjustment or lipid targets) among people of various ethnic backgrounds on six continents who did not have CVD and were at intermediate risk, found that treatment with rosuvastatin resulted in a significantly lower risk of cardiovascular events than placebo [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">Yusuf, 2016</a>]. </li></ul></li><li>A recent systematic review which quantified the effects of various doses of atorvastatin on serum total cholesterol, LDL–C, high-density lipoprotein cholesterol (HDL–C) and triglycerides in individuals with and without evidence of CVD found that atorvastatin had a dose-response effect similar to that of rosuvastatin, but it was at least three-fold less potent than rosuvastatin in reducing total and LDL-C [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">Adams, 2015</a>]. </li></ul><!-- end field af5f6519-ea63-49f1-993a-0fbc156331e4 --><!-- end item 488e28c5-e309-4e40-9c95-3d74d4eb8341 -->","subChapters":[]}]},{"id":"53622241-3a7c-50a4-bc23-e8bf11df704a","slug":"follow-up","fullItemName":"Follow up","depth":3,"htmlHeader":"<!-- begin field eb90a6e8-8731-4c20-8dca-0e229947c278 --><h3>How should I follow up someone after initiation of statin therapy for primary prevention?</h3><!-- end field eb90a6e8-8731-4c20-8dca-0e229947c278 -->","summary":null,"htmlStringContent":"<!-- begin item 036bd614-d116-4fb2-9e80-dbe17bff019c --><!-- begin field 9d5d8b27-37b1-4138-a542-049559ebd3c6 --><ul><li><strong>Measure total cholesterol, high-density lipoprotein cholesterol (HDL-C), and non-HDL cholesterol (total cholesterol minus HDL-C) levels in all people after 3 months of statin treatment. </strong><ul><li>If a greater than 40% reduction in non-HDL-C is not achieved:<ul><li>Discuss adherence and timing of dose.</li><li>Optimize adherence to diet and lifestyle measures.</li><li>Consider increasing the dose of atorvastatin if starting on less than 80 mg and the person is judged to be at higher risk of cardiovascular disease (CVD) because of comorbidities, risk score, or using clinical judgement.</li></ul></li><li>If a greater than 40% reduction in non-HDL-C is still not achieved after appropriate dose titrations of atorvastatin, or because dose titration is limited by adverse effects: <ul><li>Consider ezetimibe, co-administered with atorvastatin for people with <a class=\"topic-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/management/lipid-therapy-primary-prevention-of-cvd/#basis-for-recommendation-488\">primary hypercholesterolaemia</a> (consider seeking specialist advice).</li></ul></li></ul></li><li><strong>Recheck liver function tests (LFTs) within 3 months of starting treatment, and again at 12 months. </strong>Further monitoring is not necessary unless clinically indicated (for example symptoms or signs of hepatotoxicity develop). </li><li><strong>Review statin treatment annually. </strong><ul><li>Discuss adherence to treatment and lifestyle modification, and address CVD risk factors. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a> for more information.</li><li>Consider performing a non-fasting blood test for non-HDL-C to inform the discussion.</li></ul></li><li><strong>Routinely monitor for adverse effects of lipid modification therapy.</strong><ul><li>If unexplained muscle symptoms (such as pain, tenderness, or weakness) develop:<ul><li>Check creatine kinase (CK) — do not measure creatine kinase levels in asymptomatic people. </li><li>Explore other possible causes of muscle pain or weakness and raised CK (if present) if they have previously tolerated statin therapy for more than 3 months. </li><li>Stop statin treatment if CK is five or more times the upper limit of normal. </li><li>Consider stopping treatment if muscular symptoms are severe and cause daily discomfort, even if the CK levels are not more than five times the upper limit of normal. </li></ul></li><li>If other <a class=\"topic-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/prescribing-information/statins/#adverse-effects\">adverse effects</a> are reported when taking high-intensity statin treatment, discuss the following possible strategies with the person:<ul><li>Stopping statin treatment and trying again when the symptoms have resolved to check if the symptoms are related to statin, <em>or</em></li><li>Reducing the dose within the same <a class=\"topic-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/management/lipid-therapy-primary-prevention-of-cvd/#grouping-of-statins\">intensity group</a>, <em>or</em></li><li>Changing to a statin in a <a class=\"topic-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/management/lipid-therapy-primary-prevention-of-cvd/#grouping-of-statins\">lower intensity group</a>.</li></ul></li><li>Seek specialist advice about treatment options if treatment is still not tolerated after three different statins have been tried for people at high risk of CVD, for example, people with chronic kidney disease, diabetes mellitus, or genetic dyslipidaemias. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/chronic-kidney-disease/\">Chronic kidney disease - not diabetic</a>, <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-1/\">Diabetes - type 1</a>, <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/hypercholesterolaemia-familial/\">Hypercholesterolaemia - familial</a> for more information.</li><li>Consider treatment with ezetimibe for people with <a class=\"topic-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/management/lipid-therapy-primary-prevention-of-cvd/#basis-for-recommendation-488\">primary hypercholesterolaemia</a> who have clinically significant adverse effects with statin treatment. </li></ul></li></ul><!-- end field 9d5d8b27-37b1-4138-a542-049559ebd3c6 --><!-- end item 036bd614-d116-4fb2-9e80-dbe17bff019c -->","subChapters":[{"id":"2b7930ce-b854-5a08-8fd1-ac633d51c04f","slug":"basis-for-recommendation-aa4","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field dcae0074-75cd-44cb-829e-bc22cb4d14e8 --><h4>Basis for recommendation</h4><!-- end field dcae0074-75cd-44cb-829e-bc22cb4d14e8 -->","summary":null,"htmlStringContent":"<!-- begin item aa423800-08fe-4434-8d3a-783943266ad4 --><!-- begin field bd237559-d41e-4741-8eec-e95f80e2774f --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">NICE, 2016a</a>], the NICE technology appraisal <em>Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">NICE, 2016b</a>], the Scottish Intercollegiate Guidelines Network (SIGN) <em>Risk estimation and the prevention of cardiovascular disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">SIGN, 2017</a>], and the manufacturer's Summary of Product Characteristics for atorvastatin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">ABPI, 2018</a>].</p><!-- end field bd237559-d41e-4741-8eec-e95f80e2774f --><!-- end item aa423800-08fe-4434-8d3a-783943266ad4 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}